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ABSTRACT
The tumour and neuron interaction has a significant impact upon disease 
progression and the patients quality of life. In breast cancer patients, it is known 
that there is an interaction between the tumour microenvironment and the sensory 
neurons to influence the progression of cancer as well as pain, though these 
mechanisms still need to be clearly defined. Here it is demonstrated that in a rodent 
orthotopic model of breast cancer (MDA MB 231) there was an increase in nerve 
fibre innervation into the tumour microenvironment (protein gene product 9.5), 
which were calcitonin gene related peptide positive C fibre nociceptors. In contrast, 
there was a reduction in myelinated nerve fibres (NF200). A sensory neuronal cell 
line was cultured in response to conditioned media from MDA MB231 and MCF7 
as well as vascular endothelial growth factor-A (VEGF-A). All these experimental 
conditions induced sensory neuronal growth, with increased formation of collateral 
axonal branches. Furthermore, it was demonstrated that MDA MB231 and VEGF-A 
induced sensory neuronal sensitisation in response to capsaicin a TRPV1 agonist. MDA 
MB231 induced neuronal growth was suppressed by VEGFR2 inhibition (ZM323881 
and neutralising antibody DC101), in addition both MDA MB231 and VEGF-A induced 
neurite growth was attenuated by the inhibition of ARP2/3 complex through co-
treatment with CK666. This demonstrates that breast cancer can interact with the 
sensory nervous system to drive neuritogenesis through a VEGF-A/VEGFR2/ARP2/3 
mediated pathway.
INTRODUCTION
Cancer remains one of the main causes of mortality 
worldwide though survival rates have greatly improved 
during the last couple of decades, with many instances 
of cancer survival now above 90%. It is important to 
appreciate that the burden of the disease lies not only in the 
mortality rates, but also in those living with this disease. 
The tumour microenvironment and the tumour-stroma 
interaction is well-studied to allow for the identification 
of new cancer treatments; however, one aspect the tumour-
neuronal interaction, is often overlooked. The process 
of cancer growth and metastasis is multi-factorial, with 
the stroma consisting of a heterogenous population of 
cell types due to inflammation, angiogenesis or nerve 
infiltration [1]. Neural invasion of cancer is common 
(breast [2] and pancreatic [3]), implicating neurons in 
cancer. Neural invasion of tumour sites is deemed to be 
an indicator of a poor prognosis, with increased PGP9.5 
peripheral nerve fibre innervation associated with 
aggressive grade III breast cancer [4] and metastasis [5]. 
Primary nerve fibres play a role in a multitude of 
physiological functions such as by regulating vascular 
function (e.g. vasodilation) through the release of pro-
angiogenic factors (e.g. calcitonin gene related peptide; 
CGRP) [6]. Communication between neurons and tumour 
sites utilise neuropeptides (e.g. nerve growth factor 
(NGF) [2, 7]) to support those key pathological events 
(angiogenesis [4] and metastasis [8]) that are key for 
cancer progression. This is highlighted by tumour induced 
expansion of sensory nerve fibre innervation, such as in 
bone metastasis [9], or conversely perineural invasion 
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of migrating cancer cells along nerve fibres utilising the 
peripheral nervous system to act as a bridge to infiltrate 
into the central nervous system [10]. Furthermore, one of 
the key symptoms indicating tumour-nerve interactions is 
pain, which is especially important for consideration of 
quality of life as 85% of breast cancer patients survive 
beyond 10 years [11]. Post-surgical pain is found in up 
to 53% of women whom have had treatment for breast 
cancer [12], and for those patients whom their disease has 
metastasised to bone, pain is also common [13]. Cancer-
induced hyperalgesia and breakthrough pain has been 
strongly associated with the pathological reorganisation 
of sensory nerves in response to the cancer (breast, 
pancreatic) environment [9, 14–16]. Aberrant nerve fibre 
sprouting has been linked to pain in a number of diseases 
such as arthritis [17] and breast cancer [9], where it is 
deemed to an indicator of disease progression [4].
Understanding the communication pathways that 
occur between tumour cells and neurons will allows us 
to identify key signalling events that cause neuritogenesis 
[15, 18] of sensory nerve fibres in cancer. We have 
identified previously that vascular-endothelial growth 
factor-A (VEGF-A) interacts with sensory neurons [19] 
and is known to be upregulated in breast cancer [20]. The 
hypothesis of this study is that breast cancer utilises the 
innate adaptability of the sensory neuron to respond to 
an environmental cue to induce sensory neuronal growth 
and activation. This study highlights that metastatic breast 
cancer induces sensory neuronal growth via a VEGF-A/
VEGF receptor 2-ARP2/3 mediated pathway.
RESULTS
Hyperinnervation of nerve fibres in a breast 
cancer rodent model
It has been previously documented that nerve fibres 
are found at high densities in breast cancer [4]. Rodent 
models of bone cancer pain derived from breast [9] and 
prostate [22], have identified hyperinnervation (aberrant 
sensory nerve fibre growth) of CGRP and NF200 positive 
sensory nerve fibres in tumourigenic tissue. Furthermore, 
nerve fibres are present in the mammary gland and have 
also been demonstrated in the primary breast tumour 
site [4]. In this study, a breast cancer rodent model of 
orthotopically injected MDA MB231 cells was used to 
determine nerve fibre density in breast tumours. Normal 
mammary gland was compared to those from tumour-
bearing mice (Rag2 and CD1 nude). The xenografts were 
stained with the pan-nerve fibre marker protein gene 
product 9.5 (PGP9.5; Figure 1A, 1C, 1E) and nociceptor 
marker calcitonin gene related product (CGRP; Figure 
1B, 1D, 1F). Representative no primary controls are 
presented for PGP9.5 (Figure 1G) and CGRP (Figure 1H). 
Image analysis showed that in the tumours there was 
increased immunoreactivity for PGP9.5 (Figure 1I, 1J; 
nerve number/field of view; Normal = 0.46 ± 0.25; 
Tumour = 1.25 ± 0.23) and CGRP (Figure 1K, 1L; nerve 
number/field of view; Normal = 0.29 ± 0.13; Tumour = 
1.29 ± 0.41) compared to non-tumour bearing mice. In 
contrast, tumour-bearing tissue samples stained for NF200 
(myelinated nerve marker; Figure 1M, 1N; nerve number; 
nerve number/field of view; Normal = 0.51 ± 0.33; 
Tumour = 0 ± 0.00) showed no significant differences with 
non-tumour bearing tissue (Figure 1O, 1P).
Breast cancer cell line-conditioned media 
stimulates sensory neuron growth
Vascular endothelial growth–A (VEGF-A) 
expression is known to be upregulated in breast cancer 
[23, 24] and in the breast cancer cell lines [25]. Using 
an orthotopic breast cancer model (Figure 2A normal 
mammary tissue, Figure 2B orthotopic breast cancer 
tissue) demonstrated an increase in VEGF-A increase 
in the tumour tissue (Figure 2C; Normal = 3.21 ± 0.35 
ID; Tumour 4.20 ± 0.25 ID; ID = integrated density). 
VEGFR2 is expressed in sensory nerve terminals 
(Figure 2D) and is colocalised with a pan neuronal marker, 
PGP9.5 (Figure 2E; Overlay Figure 2F). In addition, it is 
expressed in L5 sensory DRG neurons (Figure 2G; no 
primary control Figure 2H) [26, 27]. Sensory neurons 
were treated with VEGF-A
165
a ± VEGFR2 inhibitor; 
ZM323881 (Figure 2I–2K; representative images). 
VEGF-A
165
a treatment induced a significant increase in 
neurite growth in sensory neurons versus sensory neurons 
cultured in normal media (Figure 2L; normal media = 
18.88 ± 7.82 µm; VEGF-A
165
a+vehicle = 82.14 ± 10.83 
µm). VEGFR2 activity was inhibited using ZM323881 
which led to suppression of VEGF-A
165
a induced sensory 
neuron growth (Figure 2L; VEGF-A
165
a+ZM323881 = 
43.05 ± 5.01 µm). Furthermore, VEGF-A
165
a induced 
increasee in total sensory neuron growth when compared 
to vehicle was significantly reduced by CK666 treatment 
(Figure 2M; normal media = 32.46 + 7.23 µm, VEGF-
A+Vehicle = 72.84 ± 11.38 µm; VEGF-A+CK666 = 29.69 
± 8.57 µm; Representative images Figure 2N; Normal 
media, Figure 2O; VEGF-A
165
a+Vehicle, Figure 2P; 
VEGF-A165a+ CK666). Ck666 treatment did not induce 
cell death (data not shown).
The sensory neuronal cell line, 50B11, was 
cultured in the presence of (Figure 3A) normal media, 
conditioned media taken from (Figure 3B) MDA MB 
231, (Figure 3C) MCF-7 or (Figure 3D) VEGF-A
165
a as 
well as (Figure 3E) unconditioned cancer cell line media 
for 24 hrs to determine neurite growth. MCF-7 and 
MDA MB 231 media led to increased average neurite 
length (Figure 3F; Normal = 19.99 ± 1.53 µm; Uncon 
= 18.94 ± 1.37 µm; MDA MB231 = 29.08 ± 1.35 µm, 
MCF = 33.43 ± 1.55 µm; VEGF-A = 35.57 ± 2.696 µm), 
total neurite number (Figure 3G), total growth per cell 
(Figure 3H) and maximum neurite length (Figure 3I) 
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when compared to those cells cultured in normal media 
and unconditioned media. VEGF-A
165
a has previously 
been shown to induce neurite growth [19], and acts 
as a positive example in these studies (Figure 3A–3I). 
Furthermore, MDA MB 231 conditioned media led 
to sensitisation of DRG sensory neuron responses to 
capsaicin, a TRPV1 agonist when compared to normal 
media (Figure 3J; Normal = 5.35 ± 1.55 Ca2+ AUC; 
MDA MB 231 = 8.79 ± 0.84 Ca2+ AUC). In addition, 
VEGF-A
165
a also led to increased TRPV1 responses in 
DRG sensory neurons when compared to vehicle (Figure 
3K; Normal = 0.69 ± 1.17 Ca2+ AUC vs VEGF-A = 7.16 
± 3.89 Ca2+ AUC) as previously reported [27].
Inhibition of VEGFR2 with DC 101 (rat monoclonal 
antibody), led to the inhibition of MDA MB231 
conditioned media induced neuritogenesis demonstrated 
by reduced individual neurite length (Figure 4A; Normal 
= 25.04 ± 1.94 µm; MCF10A = 25.67 ± 1.89 µm; MDA 
MB231 = 38.1 ± 2.23 µm; MDA MB231+IgG = 40.19 
± 1.82 µm; MDA MB231+DC101 = 23.39 ± 1.43 µm) 
and total neurite growth (Figure 4B; Normal = 28.71 ± 
2.95 µm; MCF10A = 26.79 ± 3.92 µm; MDA MB231 = 
59.21 ± 5.92 µm; MDA MB231+IgG = 47.03 ± 2.72 µm; 
MDA MB231+DC101 = 25.04 ± 2.84 µm). In addition, 
MCF10A, a normal epithelial breast cell line, conditioned 
media did not induce neuritogenesis of the sensory 
neurons (Figure 4A, 4B). Additionally, the VEGFR2 
tyrosine kinase inhibitor ZM323881 was used to inhibit 
MDA MB231 conditioned media induced sensory neuron 
growth; average neurite length (Figure 4C; Normal = 
15.46 ± 4.46 µm; MDA MB231+Vehicle = 37.81 ± 4.47 
µm; MDA MB231+ZM323881 = 16.13 ± 0.90 µm) and 
total sensory neuron growth (Figure 4D) was reduced 
with ZM323881 treatment (Representative examples of 
sensory neurons cultured in Figure 4E Normal; Figure 4F 
MDA MB231+IgG; Figure 4G MDA MB231+`vehicle; 
Figure 4H MCF10A; Figure 4I MDA MB231+DC101; 
Figure 4J MDA MB231+ZM323881).
ARP2/3-mediated MDA-MB231-induced sensory 
neuritogenesis
MDA MB 231-conditioned media induces 
neuritogenesis (Figure 3), however evidence supports 
Figure 1: Breast cancer induced sensory nociceptor aberrant growth. (A) Pan-nerve fibre (PGP 9.5) and (B) nociceptor (CGRP) 
immunoreactivity was present in the mammary tissue of an adult female mouse indicative of nerve fibre innervation. In rodent orthotopic 
models (representative images of (C–D) Rag2; [E–F] CD1) of breast (MDA MB231) cancer there was an increase in (C, E, I, J) nerve fibre 
innervation (PGP9.5). (D, F, K, L) There was an increase in CGRP positive nociceptor nerve fibre innervation in the tumour. Representative 
images of no primary controls for (G) PGP9.5 and (H) CGRP. Myelinated nerve fibre innervation was present in the (M) normal mouse 
though this was decreased in the (N–P) tumour (CD1). Arrows = nerve fibres, arrowheads = blood vessel. Scale bar = 50 µm.
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that ARP2/3 is key to sensory neuron filopodia formation. 
MDA MB 231 conditioned media led to increased neurite 
growth of sensory neurons, demonstrated by increased 
maximum neurite length (Figure 5A), percentage of cells 
with neurite growth (Figure 5B) and total neurite growth 
per cell (Figure 5C) when compared to normal media 
and unconditioned media. CK666 has previously been 
shown to inhibit neurite formation [28, 29]. Application 
of 100 µM CK666, ARP2/3 inhibitor, led to a significant 
reduction in neurite length (Figure 5A; MDA MB231+Veh 
= 87.65 ± 5.93 µm; MDA MB 231+CK666 = 37.96 ± 2.99 
µm), percentage of cells with growth (Figure 5B; MDA 
MB231+Veh = 83.7 ± 4.26%; MDA MB 231+CK666 = 
39.68 ± 5.9%), percentage cells with multiple neurites 
and total growth per cell (Figure 5C; MDA MB231+Veh 
= 127.00 ± 11.21 µm vs MDA MB231+CK666 = 25.18 
± 3.74 µm). Representative images of (Figure 5D 
Normal) sensory neurons in response to (Figure 5E) MDA 
MB231 unconditioned media, (Figure 5F) MDA MB231 
conditioned media+Vehicle and MDA MB231 conditioned 
media +CK666 (Figure 5G). 
MDA MB231 induced collateral sensory neurite 
branch formation
Sensory neuronal filopodia formation via actin and 
microtubule formation leads to axonal branch formation. 
Representative example of neurite filopodia F actin 
rich (phailloidin stained) (Figure 6A). MDA MB 231 
conditioned media led to an expansion of neurite growth 
cone area in relation to normal media (Figure 6B; Normal 
= 32.43 ± 4.88 µm2; MDA MB 231 = 81.36 ± 12.49 µm2), 
with MCF-7 and VEGF-A
165
a also resulting in an increase 
in growth cone area versus normal media (Figure 6B; 
Figure 2: VEGF-A induced sensory neurogenesis mediated by VEGFR2-ARP2/3. (A) VEGF-A immunoreactivity in normal 
mouse mammary fat pad and in an (B) MDA MB231 orthotopic model of breast cancer (CD1 mice). (C) VEGF-A is upregulated in the 
breast tumour tissue. (*p < 0.05, Unpaired T test). (D) VEGFR2 is expressed in (E) peripheral nerve terminals (PGP9.5; (F) Overlay) in 
the plantar skin and in (G) L5 DRG sensory neurons (scale bar = 50 µm). (H) No primary control of L5 DRG sensory neurons. (I) Sensory 
neurons were treated with either (J) VEGF-A
165
a + vehicle or (K) VEGF-A + ZM323881 and total neuronal growth was measured. (L) 
VEGF-A
165
a led to a significant increase in neuronal growth versus untreated cells. ZM323881 treatment attenuated VEGF-A
165
a induced 
sensory neuron growth. (M) Furthermore, VEGF-A
165
a induced sensory neuron growth was inhibited following CK666 treatment to inhibit 
ARP2/3 function. Representative images of (N) sensory neurons in response to either (O) VEGF-A
165
a + Vehicle and (P) VEGF-A+CK666. 
*P < 0.05, ***P < 0.001 Kruskal Wallis with Dunns multiple comparison. Scale bar = 20 µm.
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MCF = 69.88 ± 12.01 µm2; VEGF-A = 79.99 ± 10.25 
µm2). Collateral branching of the neurite (Figure 6C) was 
increased (normalised collateral branch number/100 µm 
neurite length) with MDA MB 231 conditioned media 
compared to normal and unconditioned media (Figure 6D; 
Normal = 7.38 ± 0.86 collateral branch number; MDA MB 
231 = 28.15 ± 2.55 collateral branch number), while MDA 
MB231 unconditioned media 8.95 + 0.96 collateral branch 
number), MCF7 conditioned media (8.32 + 1.11 collateral 
branch number) and VEGF-A
165
a (6.91 + 1.07 collateral 
branch number) did not stimulate collateral branch 
formation (Figure 6D). Furthermore, this is demonstrated 
by increased number of neurites expressing greater than 
9 collateral offshoot branches in the MDA MB 231 
conditioned media group compared to other experimental 
groups (Figure 6E).
MDA MB 231 induced collateral branch 
formation is ARP2/3 mediated
Sensory neuron average neurite length was 
increased by incubation with MDA MB231 conditioned 
media versus control (Figure 7A), with co-treatment of 
MDA MB231 conditioned media with CK666 leading to a 
significant reduction in average neurite length (Figure 7A; 
Figure 7B; MDA MB231+Veh = 57.20 ± 4.54 µm; MDA 
MB231+CK666 = 34.50 ± 7.22 µm; MCF+Veh = 53.68 + 
4.45 µm; MCF+CK666 = 25.94 ± 3.06 µm),  compared to 
normal media. There was no change in neurite length in 
normal treatment treated with CK666 (Figure 7A). MCF-
7 induced neurite growth was also inhibited by CK666 
treatment (Figure 7A). Both MDA MB231 and MCF-
7 induced neurite growth cone area were inhibited by 
Figure 3: MDA MB231 and MCF7 breast cancer cell lines induce sensory neuronal growth. A sensory neuronal cell line 
(A) 50B11 was exposed to conditioned media from (B) MDA MB231 and (C) MCF7 breast cancer cell lines as well as (D) VEGF-A and 
(E) unconditioned media. Scale bar = 20 µm. Conditioned media from MDA MB231 and MCF7 as well as VEGF-A
165
a led to an increase 
in the (F) average neurite length, (G) increased neurite number and (H) total growth per cell. (I) MDA MB231 conditioned media and 
VEGF-A
165
a led to increased maximum neurite length. (J) MDA MB231 conditioned media treated DRG sensory neurons had an increased 
capsaicin responses when compared to normal media treated DRG sensory neurons. Furthermore, (K) VEGF-A
165
a increased capsaicin 
induced sensory DRG neuronal responses versus vehicle treated DRG neurons (n = 8 per experimental group). *P < 0.05, **P < 0.01, 
***P < 0.001 Unpaired T test or Kruskal Wallis with Dunns multiple comparison. Scale bar = 20 µm.
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CK666 treatment (Figure 7B; MDA MB231+Veh = 61.66 
± 6.07 µm2; MDA MB231+CK666 = 26.08 ± 2.97 µm2; 
MCF+Veh = 71.81 ± 10.63 µm2; MCF+CK666 = 28.94 ± 
4.19 µm2), with normal media being unaffected by CK666 
treatment (Figure 7B). Tortuosity of actin filaments 
were reduced by CK666 treatment in MDA MB 231 
and MCF-7 conditioned media treated neurons (Figure 
7C; MDA MB 231+Veh = 0.64 ± 0.03 Tortuosity ratio; 
MDA MB 231+CK666 = 0.77 ± 0.01 Tortuosity ratio; 
MCF+Veh = 0.62 ± 0.03 Tortuosity ratio; MCF+CK666 
= 0.76 ± 0.01 Tortuosity ratio). Representative images of 
all experimental groups ± CK666 (Figure 7D normal ± 
vehicle; Figure 7E MDA MB231 ± Vehicle; Figure 7F 
MCF7 ± Vehicle; Figure 7G Normal ± CK666; Figure 
7H MDA MB231 ± CK666; Figure 7I MCF7+CK666). 
MDA MB231 induced collateral neurite branch formation 
was decreased by ARP2/3 inhibition through CK666 
inhibition (Figure 8A, 8B; Representative images of all 
experimental groups (Figure 9). Additionally, this was 
represented by a CK666 inhibition of MDA MB 231 
induced increase in the number of collateral branches per 
neurite (Figure 8A; MDA MB231+Veh = 15.42 ± 1.68 
vs MDA MB231+CK666 = 9.25 ± 1.93). There was no 
difference when comparing vehicle and CK666 treatment 
in normal media (Figure 8A–8B). MDA MB231 led to an 
increase in the number of collateral branches that were 
positive for tubulin (Figures 8C, 9A–9N) therefore these 
were classified as mature axonal collateral branches as 
previously termed [28]. CK666 inhibited MDA MB 231 
induced tubulin positive collateral branch formation 
(Figures 8C, 9G–9P; MDA MB231+Veh = 64.97 ± 4.67% 
vs MDA MB231+CK666 = 51.39 ± 4.85%).
DISCUSSION
The role of the neuro-tumour microenvironment 
is still unclear. It is appreciated that the nervous system 
interacts with the tumour, leading to advancement 
of breast cancer [2, 4]. Furthermore, evidence now 
demonstrates that this interaction may have further 
Figure 4: MDA MB231 breast cancer cell line induces sensory neuronal growth via VEGFR2 activation. (A and B) MDA 
MB231 conditioned media induced an increase in (A) average neurite length and (B) total neurite growth of sensory neurons when compared 
to normal media and conditioned media from MCF710A. (A–B) MDA MB231 conditioned media induced sensory neuroritogenesis was 
inhibited with VEGFR2 neutralising antibody DC101 when compared to rat IgG. Furthermore, inhibition of VEGFR2 using ZM323881 
led to inhibition of the MDA MB231 conditioned media induced increase in sensory neuron (C) average neurite length and (D) total 
neuron growth. Representative images of sensory neurons in (E) normal media conditions, (F) MDA MB231 conditioned media + IgG, 
(G) MDA MB231 conditioned media + Vehicle, (H) MCF10A conditioned media, (I) MDA MB231 conditioned media + DC101 and (J) 
MDA MB231 conditioned media + ZM323881. ***P < 0.001 Unpaired T test or Kruskal Wallis with Dunns multiple comparison. Scale 
bar = 20 µm.
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implications in relation to tumour support and metastasis 
[1, 5, 30]. Investigating the interaction between cancer 
and the sensory neuron is key to providing a greater depth 
of understanding in cancer biology. In this study, the 
interaction between breast cancer and the sensory neurons 
is explored to determine the mechanisms that underlie 
breast cancer induced neuritogenesis.
Understanding the neuro-cancer interaction is 
crucial as it has been implicated in disease progression 
with increases in nerve innervation present in the primary 
breast tumour site [4]. Current literature demonstrates a 
significant neuro-cancer interaction whereby in human 
and rodent studies, there is an expansion of sensory nerve 
innervation patterns in tumourigenic tissue, which is 
inclusive of breast [5, 9] and pancreatic [31] cancer. This 
is strongly associated with pain. Here we present that 
nerve fibres (PGP9.5+ive) innervate breast tumour sites 
(MDA-MB231), with these determined to be nociceptive 
sensory neurons (CGRP+ve). This is comparable to 
previous studies [9, 14, 15]. However, in contrast to the 
literature [22], myelinated NF200+ve nerve fibres did not 
innervate the tumour in this breast cancer rodent cancer 
model, though our study investigates a primary site versus 
the published work which is a metastatic site. 
The increase in PGP9.5-positive staining in the 
breast tumour supports the notion that cancer induces 
nerve fibre growth, however the mechanisms by which 
these interactions occur are still being elucidated. NGF is 
a key candidate in the pathological growth and aberrant 
sprouting of neurons in cancer, and has been shown to 
be responsible for increased pain in cancer [9, 14]. The 
fact that sensory nerves elongate in response to these 
Figure 5: ARP 2/3 regulation controls MDA MB231 induced sensory neuronal growth. MDA MB231 induced increase in 
(A) maximum neurite length, (B) percentage of neurons with neurites and (C) total growth per neuron were attenuated by ARP2/3 inhibitor 
CK666. Representative images sensory neurons in response to experimental conditions; (D) normal media, (E) MDA MB231 unconditioned 
media, (F) MDA MB231 conditioned media + Vehicle, (G) MDA MB231 conditioned media + CK666. *P < 0.05, **P < 0.01, ***P < 0.001 
Kruskal Wallis with Dunns multiple comparison. Scale bar = 20 µm.
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tumour derived mediators may have implications for the 
way in which we understand cancer biology. Rather than 
simply causing the sprouting of existent nerves around the 
tumour, these mediators may also cause nerves to grow 
into the tumour, moving up NGF and VEGF gradients 
[42] as well becoming hyperactive as demonstrated here 
through enhancement of sensory neuronal TRPV1 activity. 
This would induce peripheral nociceptor sensitisation and 
lead to the development of chronic pain in cancer [32]. 
In addition, our study highlights not only an increase 
in free nerve endings and sensory nerve activity but 
also associations with increased immunoreactivity with 
blood vessels. Increased nerve activity induces increased 
vascular permeability via for example CGRP [6, 30] and 
such activity has been linked to cancer disease progression 
[30]. Therefore it is plausible that breast cancer growth 
and migration, could be suppressed following inhibition 
of neuronal vascular interactions. 
Cancer is associated with angiogenesis, immune 
cell infiltration and in case of bone metastasis skeletal 
fractures. Majority of work to date concentrates on 
in vivo studies utilising a heterogeneous population of 
cell types that encompass the tumour stroma [9, 22, 30] 
highlighting the importance of understanding the nervous 
system involvement in cancer biology. However these do 
not take into account specific mechanisms by which these 
pathologies develop. Such tumour environments can lead 
to sensory nerve compression and sensory nerve terminal 
interaction with inflammatory and cancer cell types. These 
factors are all contributory to neurogenesis with a great 
body of work highlighting this in cancer pain, however 
still many questions remain unanswered. Stereotypically 
in human and rodent studies cancer pain is attributable to 
activation of the peripheral sensory neuron [32]. A number 
of inflammatory mediators; that have expression increased 
in cancer and accompany cancer disease progression, are 
Figure 6: MDA MB231 cancer cells drive sensory neuronal growth cone expansion and collateral branch formation. 
(A) Sensory DRG neurons treated with conditioned media from MDA MB231 and MCF7 as well as VEGF-A demonstrated increased 
growth cone area (Scale bar = 10 µm). (B) In addition, the number of collateral branches formed was increased in sensory neurons exposed 
to conditioned media from MDA MB231 cells when compared to normal media, unconditioned media, MCF7 and VEGF-A. (C) This 
was further demonstrated by MDA MB231 conditioned media inducing a greater percentage of sensory neurons to have greater numbers 
neurite branches (Scale bar = 20 µm). Representative images of sensory neuron (D) growth cone and (E) collateral branches. *P < 0.05, 
***P < 0.001 Kruskal Wallis with Dunns multiple comparison.
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granulocyte-macrophage colony-stimulating factors (GM-
CSF) [15], VEGF-A [27], nerve growth factor (NGF) 
[33] and glial cell derived neurotrophic factor (GDNF) 
[34] are known to induce sensory neuron activation and 
pain; neuropathic and inflammatory pain [15, 27, 35, 36]. 
Both VEGF-A and NGF sensitise peripheral sensory 
nerve fibres to a number of sensory stimuli [27, 33] and 
for example lead to activation of heat sensing channel, 
transient receptor vanilloid 1 channel TRPV1 [27]. 
Despite being best known as a pro-angiogenic factor, 
recent research has shown that VEGF-A is not restricted 
to its angiogenic capabilities [27]. Previous studies 
demonstrate that VEGF-A can drive sensory neuronal 
growth [19, 37] and is neuroprotective [38, 39]. Studies 
presented here demonstrate that those tumour derived 
mediators directly drive sensory neuronal function (growth 
and sensory neuron TRPV1 activation) in a VEGF-A 
dependent manner. In addition, MDA MB231 and MCF7 
cancer cells induce sensory neurite growth. Furthermore, 
inhibition of VEGFR2 through either ZM323881 or 
DC101 treatment inhibited MDA MB231 induced neurite 
growth highlighting that VEGF-A/VEGFR2 signalling is 
an important regulator of breast cancer induced sensory 
neuritogenesis. Therefore such a VEGF-A enriched 
tumour environment would propose to induce neuronally 
mediated CGRP nerve fibre branching, hyperactivity and 
induce angiogenesis for tumour support.
However, there are a multitude of mediators and 
mechanisms that regulate sensory neuronal function, many 
of which have not been explored in relation to cancer-
neuron interactions. It is important to note that many have 
investigated the molecular components of sensory neurite 
growth in relation to neuroregeneration and synaptogenesis 
in the nervous system, primarily targeting NGF induced 
TrkA activation which in turns leads to neurite growth 
[40]. NGF drives neurite growth through expansion 
of the axonal growth cone as well as directionality by 
targeting NGF rich areas [29, 40]. In addition to increases 
in axonal length, NGF drives neurite branching along the 
axonal main trunk creating collateral nerve growth [41]. 
The formation of such collateral branching is due to the 
emergence of axonal filopodia from actin rich patches. 
It has been shown that the ARP2/3 complex provides 
the framework to initiate such filopodia expansion, with 
Figure 7: CK666 inhibited sensory neuritogenesis induced by both MDA-MB-231 and MCF7. MDA MB231 and MCF7 
induced sensory neuron growth; (A) average neurite length and (B) growth cone area versus normal media. This was inhibited by CK666 
administration. Furthermore, (C) the tortuosity of the actin filaments was increased in CK666 sensory neurons indicative of a reduction 
in actin filament formation and straightness of such fibres Representative images of the sensory neuronal cell line 50B11 under varying 
experimental conditions; (D) normal media + vehicle, (E) MDA MB231 conditioned media + vehicle, (F) MCF7 conditioned media + 
vehicle, (G) normal media + CK666, (H) MDA MB231 conditioned media + CK666, (I) MCF7 conditioned media + CK666. *P < 0.05, 
***P < 0.001 Kruskal Wallis with Dunns multiple comparison. Scale bar = 20 µm.
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NGF inducing increasing frequency of such sites along 
the sensory nerve axon [28, 41]. This supports the notion 
that NGF drives expansion of the sensory nerve fibres in 
tumours. As well as MDA MB231 and MCF7 induced 
neurite growth, the growth cone area is also increased 
with these parameters of sensory neuron growth also 
associated with VEGF-A treatment. It is highly plausible 
that additional tumour derived factors are associated with 
this as NGF secretion is not significantly different between 
MCF-7 and MDA MB 231 cells [42]. Expression levels 
of proteins secreted by MDA MB231 such as VEGF-A 
[43, 44] and insulin-like growth factor binding proteins 
are higher than in MCF-7 [45] and this is implicated 
in collateral branch formation. Previous literature has 
suggested that ARP2/3 is crucial for actin polymerisation, 
and therefore for sensory neurite elongation and 
directionality [29]. Therefore in an NGF rich environment, 
as is produced by many tumours [9], ARP2/3 activation is 
liable to be widespread with increase frequency in actin 
rich/ARP2/3 axonal patches [28], ultimately leading to 
increased neurite growth and branching. CK666 inhibition 
prevented MDA MB231, MCF7 and VEGF-A neurite 
growth as well as reducing MDA MB231 and MCF7 
induced growth cone expansion highlighting regulation 
of VEGF-A induced neurogenesis. Additionally, ARP2/3 
allows for the formation of filamentous actin, however 
CK666 treatment led to a reduction in the formation of 
F actin structures. Surprisingly, MDA MB231 led to 
increased collateral branching from the sensory nerve 
axon, whereas VEGF-A and neither MCF7 induced 
increases in collateral branching. This was reduced by 
CK666 treatment, with the number of mature branches 
that had been penetrated by tubulin also reduced. MDA 
MB231 release greater levels of VEGF-A versus MCF7 
[44, 46] therefore it would be expected that MDA MB231 
to induce increased neurite formation as it is demonstrated 
that VEGF-A actions via VEGFR2 induce sensory neuron 
growth. However, VEGF-A alone did not induce increased 
collateral branching. This could implicate as mentioned a 
cocktail of mediators driving sensory neuritogenesis such 
as NGF, which as mentioned induces collateral neuronal 
branching, as well as plausibly epidermal growth factor 
Figure 8: MDA MB231 and MCF7 induced neuritogenesis was inhibited by CK666 administration. MDA conditioned 
media induced (A) increased number of collateral branches with (B) percentage number of the neuron population had greater than 9 axonal 
collateral branches. Furthermore, (C) treatment of neurons with MDA MB 231 conditioned media increased mature (tubulin positive) 
axonal branches. ARP 2/3 inhibition with CK666 led to a (A) reduction in total number of collateral branches induced by MDA MB231 
conditioned media treatment. In addition, CK66 administration prevented (B) the increase in the % of neurons with greater numbers 
of collateral branches induced by MDA MB231 conditioned media. (C) MDA MB231 induced mature sensory axonal fibre formation 
(phalloidin positive/tubulin positive) when compared to normal media treated neurons. CK666 treatment inhibited MDA MB231 induced 
mature collateral branch formation. *P < 0.05, ***P < 0.001 Kruskal Wallis with Dunns multiple comparison.
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(EGF) or GM-CSF. Sensory DRG neurons express EGF 
receptor [47] and it has been shown that TGFα induces 
sensory activation [48] and neuronal growth [49], where 
as EGF does not [49]. Furthermore, additional growth 
factors TGFβ inhibits neuronal growth [50] and GM-
CSF stimulates neurogenesis and bone cancer pain [15].
These alternative factors such as GM-CSF can differ 
between these pathologically distinct breat cancer cell 
lines such as in comparing basal like MDA MB231 and 
luminal A MCF7 with distinct GM-CSF derived actions 
demonstrated in MDA MB231 [51]. This differential 
expression profiles of growth factors provides an 
explanation for differential induction of collaternal branch 
formation, and highlights the complex nature of these 
neuro-cancer interactions which we begin to decipher in 
this study.
These studies highlight that the tumour environment 
directly acts upon the sensory neuron to drive alterations 
in sensory neuronal function through VEGF-A/VEGFR2 
induced sensory neuronal activation and aberrant neuronal 
growth. By identifying these signalling pathways it allows 
for further understanding of cancer biology, providing 
crucial evidence in how the sensory neuron-tumourigenic 
interface controls cancer and pain development.
MATERIALS AND METHODS
All procedures involving the mice were performed 
in accordance with the United Kingdom Animals 
(Scientific Procedures) Act 1986, the UK Home Office 
and ARRIVE guidelines under project license authority 
PPL40/3559 using archived tissue. Ethical approval was 
granted by the University of Nottingham Animal Welfare 
and Ethical Review Board. CD-1 nude female mice at 6 
to 8 weeks of age were obtained from Charles River, UK 
and Rag2−/− female mice. The animals were provided 
food and water ad libitum. MDA-MB-231 cells, with 
viability of > 90%, which had been maintained in vitro in 
RPMI culture medium (Sigma, UK) containing 10% (v/v) 
heat inactivated foetal bovine serum (Sigma, Poole, UK) 
Figure 9: MDA MB231 induced mature sensory axonal neurite formation via ARP2/3. MDA MB231 induced sensory 
neuronal growth as well as increased neurite formation. Representative images demonstrate that when compared to (A–C) normal media 
+ vehicle, (D–F) MDA MB231 conditioned media led to an increase in mature sensory neurite formation (phalloidin positive and tubulin 
positive). Furthermore, treatment with CK666 did not alter sensory neuronal growth in (G–I) normal + media but (J–L) inhibited MDA 
MB231 induced mature collateral branch formation. High magnification representative images demonstrate that (N) MDA MB231 
conditioned media induces collateral branch formation when compared to (M, O) normal media ± CK666 and (P) MDA MB231+CK666. 
Low magnification images = 20 µm (A–L). High magnification images = 10 µm (M–P).
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& 2 mM L-glutamine (Sigma, UK) at 37°C in 5% CO
2, 
were be re-suspended, for in vivo administration, in sterile 
growth factor reduced matrigel at 2 × 106 cells/100 ul 
(1 to 2 × 107 cells per ml) and 100 ul of cell suspension was 
injected into the mammary fatpad for tumour initiation. 
For primary cell culture calcium experimentation C57Bl6 
male mice were used.
Immunohistochemistry
MDA-MB-231 xenografts grown in the mammary 
fat pad of Rag 2−/− and CD1-nude mice or tissue 
from uninjected animals as control tissue were fixed 
in formaldehyde and then dehydrated in sequential 
concentrations of methanol, followed by immersion in 
xylene and paraffin wax (BDH, cat 36107 7E). Sections 
were cut at 10 µm thickness at approximately 30 μm 
intervals and mounted onto Thermo Scientific Menzel-
Gläser Superfrost microscope slides. The slides were then 
incubated overnight at 40°C.
For immunohistochemistry sections were immersed 
in xylene for 15 minutes before twice being immersed in 
100% methanol. These were washed in distilled water 
twice, each for five-minute intervals. The slides were then 
submerged in citrate buffer (pH 6.0) and heated at 98°C 
for thirty minutes. Sections were then placed under the 
running water prior to use. Sections were washed three 
times in PBST (0.2% triton x-100) for five minutes. 
Subsequently, 3% H
2
O
2
 was applied to each slide for 
five minutes and then washed with PBS. This step was 
repeated. Slides were then exposed to PBST for five 
minutes prior to incubation in blocking solution (5% FBS 
and 10% BSA in PBST) for one hour at room temperature. 
Sections were then washed three times in PBS for five 
minutes. Primary antibodies were prepared in blocking 
solution and sections were incubated overnight at 4°C. 
Primary antibodies used were: rabbit anti-VEGF-A (1 in 
100 Santa Cruz A20), rabbit anti- calcitonin gene related 
peptide (CGRP: 1:2000; EMD Millipore) and rabbit 
anti- protein gene product 9.5 (PGP9.5; 1:250; EMD 
Millipore). Slides were then washed in PBS three times 
for five minutes per wash. Sections were incubated with 
donkey biotinylated anti rabbit IgG (1:500; Jackson) in 
PBST for 90 minutes at room temperature. ABC reagent 
was prepared according to the instructions given in the 
Vectastain ABC kit (Vector Laboratories) and left to 
stand for 30 minutes. Sections were washed a further 
three times with PBS for five minutes. Vectorstain was 
applied to the slides and left for thirty minutes at room 
temperature. Slides were washed in PBS washes three 
times. The DAB stain (Vector Laboratories) was prepared 
as indicated in the given instructions and applied to each 
slide for two minutes. Each slide was then immediately 
washed in distilled water for five minutes. Slides were 
then washed twice in methanol, followed by xylene for 
10 minutes. DPX was applied to the slides and coverslips 
were applied. Slides were imaged using a Leica DMLB 
microscope at 40× objective and images were collected 
using Leica QWin V3 software.
Immunofluorescence 
Dorsal root ganglia Lumbar (L) 5 and plantar surface 
of hindpaws were excised and immersion fixed in 4% 
paraformaldehyde. This was followed by tissue immersion 
in 30% sucrose for 24 hours 4°C. Tissue was frozen in 
OCT and stored at −80°C until processing. Tissue sections 
were cut to thickness of 6 µm for dorsal root ganglia and 
20 µm for plantar skin. Slides were washed in PBS and 
was followed by PBST for five minutes prior to incubation 
in blocking solution (5% FBS and 10% BSA in PBST) for 
one hour at room temperature. Sections were then washed 
three times in PBS for five minutes. Primary antibodies 
were prepared in blocking solution and sections were 
incubated overnight at 4°C. Primary antibodies used were: 
rabbit anti- vascular endothelial growth factor receptor 2 
(VEGFR2: 1:100; Cell Signalling) and mouse anti- protein 
gene product 9.5 (PGP9.5; 1:10; Abcam). Slides were 
then washed in PBS three times for five minutes per wash. 
Sections were incubated with secondary antibody (1:1000; 
anti-rabbit alexafluor 488 or anti-mouse alexafluor 555) 
in PBST for 90 minutes at room temperature. Slides were 
washed in PBS and mounted with vectorshield (Vector 
Laboratories). Images were acquired using a Leica SPE 
confocal microscope.
Neuronal growth assay
A sensory neuronal cell line, 50b11s, was used 
as previously described [19, 21]. Cells were cultured 
in Neurobasal Media (ThermoFisher Scientific) 
supplemented with 10% FBS, 0.5 mM L-Glutamine, 1× 
B27 and 0.2% glucose. A 24 well plate had cover slips 
inserted and sterilised with ethanol. 5000 cells were 
placed in each well and were left for 24 hours prior to 
incubation in experimental culture condition. In each case 
75 μM Forskolin was added as previously described [19]. 
Experimental groups for conditioned media experiments 
were as follow:- (a) 400 µl complete neurobasal media, (b) 
400 µl unconditioned media, (c) 400 µl MDA conditioned 
media, (d) 400 µl MCF10A-conditioned media, (e) 400 
µl MCF-7-conditioned media, or (f) 400 µl 2.5 nM 
VEGF in complete neurobasal media. Conditioned media 
was extracted from cells having been exposed to either 
MDA MB231 (RPMI supplemented with 10% FBS and 
2 mM l-glutamine), MCF-7 (Phenol Red free RPMI 
supplemented with 10% FBS and 2 mM l-glutamine) or 
MCF10A (HuMEC serum free medium supplemented 
with Bovine Pituitary Extract (BPE), HuMEC supplement 
and 100 ng/μl cholera toxin) cells for 3 days. All wells 
were made up to 800 µl by adding 400 µl supplemented 
neurobasal media. Drugs applied were DC101 8.05 μg/ml 
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(versus equivalent rat IgG control) (BioXcell), VEGF-A 
(2.5 nM R&Dsystems), ZM 323881 (100 nM Tocris) or 
CK666 (100 µM Sigma-Aldrich). Experimental repeats 
were a minimum of 4 wells per plate, with a minimum of 
3 plates per experiment.
Immunocytochemistry
Experimental plates were cultured for 24 hours and 
4% paraformaldehyde was then applied for 15 minute. 
Wells were then washed in PBS three times with PBS 
cells prior to incubation in blocking solution (PBS + 0.2% 
Tritonx-100, 5% BSA and 10% FBS) for 30 minutes. 
Phalloidin alexafluor 488 was made up in 0.2% triton 
in PBS (1 in 500 in block solution; Life Technologies) 
and added to the slides. For tubulin and actin imaging; 
cells were incubated in 4% paraformaldehyde (made up 
in PHEM buffer; 60 mM PIPES, 25 mM HEPES, 10 mM 
EGTA, 2 mM MgCl
2
, pH6.9) for 15minutes. Phalloidin 
Alexfluor 488 was added in addition to anti alpha tubulin 
(mouse; 1 in 500) for 1 hr. Coverslips were washed three 
times with PBS. For tubulin imaging anti-mouse Alexfluor 
555 (1 in 10000, Life Technologies) was added in PBS 
0.2% triton X-100). Coverslips were washed three times 
with PBS. Coverslips were removed and placed on slides 
with Fluorsave (DAPI containing, Sigma). Slides were 
imaged using a Leica SPE Confocal Microscope.
Calcium imaging
Dorsal root ganglia (DRG) sensory neurons were 
dissected from 4 mice per plate. Each assay contained a 
minimum of 8 wells per condition with each experiment 
repeated (minimum of 8 mice per preparation). All DRGS 
were incubated in F12 media (supplemented with 1ml 
Penicillin/Streptomycin, 15% BSA and N2). DRGs were 
added to F12 media and 0.125% collagenase (Sigma) 
for 2 hrs at 37oC. DRGs were triturated to form a cell 
suspension, which was then added to the top of a 15% 
bovine serum albumin solution. This was spun at 1900 
rpm for 10 minutes. Supernatant was disposed and pellet 
was resuspended in supplemented F12 media. 2000 cells 
per well were added to a 96 well plates that had been 
treated with poly L lysine and laminin. Cells were left for 
48 hrs prior to administration of experimental conditions 
(100 µl per well): 2.5 nM VEGF-A
165
a and MDA MB231 
conditioned media. Fluo4 direct assay (supplier) was used 
as according to manufacturer’s instructions. Fluo4 was 
made up 10 ml with the supplied Fluo4 direct calcium 
assay buffer. 5 mM probenecid was added. 60 µl of media 
was removed following 24 hrs exposure to experimental 
conditions. 40 ul of fluo4 was then added and left for 
1 hr at 37°C. The plate was then placed in a Victor Perkin 
Elmer plate reader. A baseline measurement was recorded 
from each well prior to drug stimulation. 20 µl of vehicle 
or 5 µM capsaicin (final working concentration 1 µM) was 
added to each well. Fluorescence emission was recorded 
and analysed.
Statistical analyses section
All data are represented as mean ± SEM and 
n numbers are presented in the accompanying figure 
legends. All results were analysed using Graphpad Prizm 
v7, Microsoft Excel and Image J. At least 5 sections 
per animal were taken from the normal and tumour 
bearing samples. The total number of CGRP or PGP9.5 
positive nerve fibres were counted per acquired image, 
and was represented as an average per animal. VEGF-A 
immunoreactivity was measured using integrated density 
(Image J plugin). Calcium responses were determined by 
calculated normalised baseline (F0 responses) and post 
drug capsaicin (F
1
) induced responses from obtained 
raw data values. Consequently drug responses (F
1
) were 
determined as a fold change from F0 and represented as 
AUC.
All in vitro experimentation was carried out 
via acquisition of a minimum of 5 images per well. A 
minimum of 4 wells per experimental replicate was 
carried out and these studies were repeated. Neurite was 
determined as a phalloidin stained extension from the cell 
body, with all measurements taken from this reference 
point. Neurite parameters (average length, total neurite 
growth, neurite number and longest neurite) were all 
determined from images analysed using Image J. Image 
scale was determined and ImageJ calibrated accordingly. 
Growth cone area was determined as an outlined area 
defined in Image J. The number of phalloidin stained 
collateral branches/offshoots extending from the neurite 
were counted and normalised to length of neurite to 
allow for number per 100 µm neurite length. This was 
due to experimental conditions leading to alterations in 
neurite length thus the normalisation allowed for direct 
comparison between groups. The number of phalloidin 
and tubulin positive neurites were counted and presented 
as the percentage of phalloidin positive neurites that were 
also tubulin positive.
Abbreviations
VEGF-A: vascular endothelial growth factor A; 
VEGFR2: vascular endothelial growth factor receptor 2; 
DRG: dorsal root ganglia; PGP9.5: protein gene product 
9.5; NF200: neurofilament 200; TRPV1: transient receptor 
potential vanilloid 1; ARP2/3: actin related proteins 2/3; 
CGRP: calcitonin gene related peptide; NGF: nerve 
growth factor; PBST: phosphate buffered saline, triton 
x-100; BSA: bovine serum albumin; GMCSF: granulocyte 
macrophage colony stimulating factor; GDNF: glial cell 
line derived neurotrophic factor; TrkA: tropomyosin 
receptor kinase A; F actin: filamentous actin; EGF 
epidermal growth factor; TGF: transforming growth factor.
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